Springer Nature
Browse
12933_2018_682_MOESM1_ESM.docx (33.46 kB)

MOESM1 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Download (33.46 kB)
journal contribution
posted on 2018-03-14, 05:00 authored by Julio Rosenstock, Vlado Perkovic, John Alexander, Mark Cooper, Nikolaus Marx, Michael Pencina, Robert Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli Broedl, Hans-Juergen Woerle, Jyothis George, Maximilian Eynatten, Darren McGuire
Additional file 1. Full inclusion and exclusion criteria for CARMELINAÂŽ.

Funding

Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

History

Usage metrics

    Cardiovascular Diabetology

    Categories

    Keywords

    Diabetes mellitus, type 2Cardiovascular diseasesDiabetic nephropathiesDipeptidyl-peptidase IV inhibitorsLinagliptinClinical trial, phase IVResearch designTreatment outcome

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC